SCHEMBL21246043

SCHEMBL21246043

CCNc1cccn(-c2cccc(F)c2)c1=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.44
THRB P10828 1/20 0.44
ALDH1A1 P00352 3/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
SYK P43405 1/20 0.40
KMT2A Q03164 3/20 0.40
MEN1 O00255 2/20 0.40
FAAH O00519 1/20 0.40
MGLL Q99685 1/20 0.40
GAA P10253 1/20 0.39
TYK2 P29597 3/20 0.39
USP2 O75604 1/20 0.38
CASP1 P29466 1/20 0.38
BRCA1 P38398 1/20 0.38
CASP7 P55210 1/20 0.38
KDM4E B2RXH2 1/20 0.37
KEAP1 Q14145 1/20 0.37
ALDH1A2 O94788 1/20 0.36
ALDH1A3 P47895 1/20 0.36
PTGER3 P43115 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21258570 0.84 RXFP1 (0.44) ALDH1A1KMT2AMEN1TYK2USP2
SCHEMBL20687683 0.84 TYK2 (0.44) POLBTHRBALDH1A1L3MBTL1SYK
SCHEMBL20687711 0.81 L3MBTL1 (0.41) POLBTHRBALDH1A1L3MBTL1SYK
SCHEMBL20697237 0.76 ELANE (0.44) ALDH1A1KMT2AMEN1GAATYK2
SCHEMBL16812361 0.73 POLB (0.47) POLBTHRBALDH1A1L3MBTL1SYK
SCHEMBL16019397 0.70 L3MBTL1 (0.42) POLBTHRBALDH1A1L3MBTL1KMT2A
SCHEMBL23583127 0.70 POLB (0.43) POLBALDH1A1L3MBTL1KMT2AMEN1
SCHEMBL8137135 0.70 KEAP1 (0.49) POLBALDH1A1L3MBTL1KMT2AMEN1
SCHEMBL1260057 0.70 FAAH (0.46) POLBTHRBALDH1A1L3MBTL1SYK
SCHEMBL13672252 0.69 FAAH (0.52) POLBTHRBALDH1A1L3MBTL1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11046698-B2 TYK2 inhibitors and uses thereof NIMBUS LAKSHMI, INC. (US) 2021-06-29 US disclosed
US-10562906-B2 TYK2 inhibitors and uses thereof Nimbus Lakshimi, Inc. (US) 2020-02-18 US disclosed
US-20190241576-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-08-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11046698-B2 TYK2 inhibitors and uses thereof TYK2, JAK2, JAK1 POLB 1657/4885THRB 758/4885ALDH1A1 4827/4885
US-10562906-B2 TYK2 inhibitors and uses thereof TYK2, JAK2, JAK1 POLB 1657/4885THRB 758/4885ALDH1A1 4827/4885
US-20190241576-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 POLB 1657/4885THRB 758/4885ALDH1A1 4827/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.